Skip to content
Link copied to clipboard

CSL Behring hemophilia treatment approved and available

CSL Behring, King of Prussia, said Monday its treatment for hemophilia A to protect adults and children against bleeding episodes is now available to patients and physicians.

CSL Behring, King of Prussia, said Monday its treatment for hemophilia A to protect adults and children against bleeding episodes is now available to patients and physicians.

The treatment, AFSTYLA, was approved by the Food and Drug Administration in May and is designed for "long-lasting protection from bleeds" with twice weekly dosing. In a patient study of 848 adults and adolescents and 347 children, bleeding events were controlled with no more than two weekly infusions of the medicine, the company said.

The company said 81 percent of bleeds in adults and adolescents, and 86 percent of bleeding events in pediatric patients were controlled by only one infusion per week.

CSL Behring, which employs more than 500 at its King of Prussia headquarters, makes products to treat bleeding disorders, such as hemophilia and Von Willebrand disease, and immune deficiency diseases. The company is a unit of Australia's CSL Ltd.

lloyd@phillynews.com

215-854-2831

@LoydLinda